Navigation Links
PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
Date:4/28/2009

e:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) - a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the DHHS Request for
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Announces $5.5 Million Public Equity Offering
2. PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
3. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
4. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
5. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
6. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
7. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
10. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
11. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Topical BioMedics, Inc., is celebrating 20 years of ... restoring hope an quality of life and contributing to ... of the innovative cellular biomedicines research that made Topricin® ... , The company was founded in 1994 in a ... of research, and Topricin inventor), Aurora Paradise (COO) and ...
(Date:9/22/2014)... -- Research and Markets has announced the ... Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:9/22/2014)... (Nasdaq: NEOG ) announced today that net ... year, which ended Aug. 31, was $8,883,000 — a ... the first quarter of last year. Adjusted for a ... share in the current quarter were $0.24, compared to ... increased 15% to $67,599,000, from the previous year,s first ...
(Date:9/22/2014)... September 22, 2014 The US ... mixed note as the Dow Jones Industrial Average finished ... at 4,579.79, down 0.30%. The S&P 500 finished the ... six out of ten sectors finished on a positive ... the day at 751.48, up 0.10%, with the index ...
Breaking Biology Technology:Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
... following Webcast:, What: Transgenomic Inc. Fourth Quarter ... Conference Call, When: Thursday, February 28, 2008 ... How: Live over the Internet -- Simply log ... address above., To access the call via telephone, call ...
... 28 Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) announced today that it ... March,6, 2008, before the U.S. financial markets open. Management will provide a,Company ... 6, 2008, at 9:00 a.m. EST., Investors and ... ...
... New England Journal of Medicine, led by researchers at ... University of Massachusetts Medical School (UMMS), indicates a declining ... the first demonstration of a link between two independent ... has offered universal newborn screening to detect cystic fibrosis ...
Cached Biology Technology:Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008 2Data show a decline in cystic fibrosis since introduction of prenatal carrier screening 2
(Date:9/19/2014)... resource unveiled today by researchers from several Harvard ... provides both experienced and aspiring researchers with the ... operate robots made from soft, flexible materials. , ... cutters, and other advances in manufacturing technology, soft ... Using principles drawn from conventional rigid robot design, ...
(Date:9/19/2014)... of Oklahoma biology professor will study multifunctional and ... movements with a National Science Foundation grant in ... , Ari Berkowitz, professor in the Department of ... focus on the differences between the multifunctional and ... neurotransmitters they use and what connections they make. ...
(Date:9/19/2014)... Imagine you are a species which over thousands of years ... exposed to a substance that makes the cold dangerous for ... Enchytraeus albidus , and the cold provoking substance, called ... cosmetics. , Nonylphenol is suspected of being a endocrine disruptor, ... It inhibits the worm,s ability to protect the cells in ...
Breaking Biology News(10 mins):Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... This press release is available in ... scientists working with the University of Illinois at Urbana-Champaign ... soybean yields by an average 23 percent. Randy ... Research Service Soybean/Maize Germplasm, Pathology, and Genetics Research Unit ...
... DC, Aug. 22The Martin Luther King, Jr. Health Equity ... Multicultural and Minority Medicine (IAMMM), opens today as the ... opens to the public on the National Mall. Both ... focusing tightly on the health status of minorities and ...
... a five-year grant is considered a long-term grant, Alan R. Templeton, ... University in St. Louis, has managed to follow some of the ... Early in his career he studied parthenogenesis, or virgin birth, in ... Hawaii. "Drosophilia have fast generation times," he says, "but I ...
Cached Biology News:Breeding ozone-tolerant crops 2MLK, Jr. Health Equity Summit opens as memorial to Dr. King is unveiled in DC 2Restoration as science: case of the collared lizard 2Restoration as science: case of the collared lizard 3Restoration as science: case of the collared lizard 4Restoration as science: case of the collared lizard 5Restoration as science: case of the collared lizard 6Restoration as science: case of the collared lizard 7Restoration as science: case of the collared lizard 8Restoration as science: case of the collared lizard 9
Purified anti-LAT...
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Request Info...
Biology Products: